SALT LAKE CITY–(BUSINESS WIRE)–Clinical
Innovations, one of the largest medical device companies exclusively
focused on labor and delivery and the neonatal intensive care unit,
today announced the official launch of the ebb Complete Tamponade
System, which is an effective treatment for postpartum hemorrhage (PPH).
Postpartum hemorrhage is one of the leading causes of maternal
mortality. As part of Clinical Innovations’ mission to improve the lives
of mothers and their babies throughout the world, ebb allows for rapid,
emergency deployment to significantly reduce or eliminate bleeding in up
to 98 percent of patients.1
With its unique, malleable polyurethane material and patented
dual-balloon design, ebb conforms to the patient’s anatomy and can help
avoid hysterectomy, according to a large prospective study published in
the American Journal of Obstetrics and Gynecology.
“Postpartum hemorrhage puts up to 200,000 mothers in the U.S. at risk
every year and can be fatal in hours if untreated. The ebb Complete
Tamponade System’s rapid-response design is an easy-to-deploy,
cost-effective solution for improving patient outcomes associated with
PPH,” said Dr. Ross McQuivey, chief medical officer for Clinical
Innovations. “We’re committed to developing safe, reliable and
innovative solutions to improve the lives of mothers and their babies,
and we’re proud to have ebb return as a core part of our growing labor
and delivery product portfolio.”
After receiving FDA clearance in January of 2016, Clinical Innovations
conducted a successful limited release where ebb has been used in
hospitals throughout the United States and Europe for the past year. “We
have had great feedback on ebb and excellent clinical results for the
treatment of PPH. We are excited to launch ebb so clinicians can utilize
this critical device to save lives throughout the world,” said Jeff
Bradford, vice president global marketing.
About Clinical Innovations
Clinical Innovations is one of the largest medical device companies
exclusively focused on labor and delivery and the neonatal intensive
care unit. Already a market leader in several categories with products
such as the Koala® Intrauterine Pressure Catheter; Kiwi® Vacuum-Assisted
Delivery System; ROM Plus® Rupture of Membranes Test; traxi® Panniculus
Retractor, ClearView Uterine Manipulator and recently added babyLance
Safety heel stick. Clinical Innovations is expanding its
global presence while directly researching and developing
state-of-the-art technologies and innovative medical devices that
fulfill its mission of improving the lives of mothers and their babies
throughout the world. Clinical Innovations is a Pritzker Group company.
For more information, visit clinicalinnovations.com.
About Pritzker Group
Pritzker Group, led by Tony and J.B. Pritzker, has three principal
investment teams: Private Capital, which acquires and operates leading
North America-based companies; Venture Capital, which provides
early-stage and growth venture funding to technology companies
throughout the United States; and Asset Management, which partners with
top-performing investment managers across global public markets.
Pritzker Group Private Capital acquires North America-based
middle-market companies with leading positions in the manufactured
products, services and healthcare sectors. The firm’s permanent,
proprietary capital base allows for efficient decision making, broad
flexibility with transaction structure and investment horizon, and
alignment with management teams focused on creating long-term value.
Pritzker Group brings significant resources, expertise and credibility
in building businesses and is an ideal partner for entrepreneur- and
family-owned companies. For more information, visit pritzkergroup.com.
1. Initial experience with a dual-balloon catheter for the management of
postpartum hemorrhage. Dildy GA, Belfort MA, Adair D, et al. Am J Obstet
Martha Arendt, 312.629.9400